Skip to main content

Advertisement

Table 1 The A570 values of different treatments on DEHs when adding virus firstly (n = 6)

From: Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

GP Concentration (μg.mL− 1) A 570 Hepatocyte protection rate (%) pGP Concentration (μg.mL− 1) A 570 Hepatocyte protection rate (%)
100 0.338 ± 0.009b 51.91 25 0.523 ± 0.008a 113.42
50 0.229 ± 0.007c 19.94 12.5 0.486 ± 0.007b 97.40
25 0.167 ± 0.010d 1.76 6.25 0.458 ± 0.007c 85.28
12.5 0.174 ± 0.006d 3.81 3.125 0.380 ± 0.006d 51.52
0(VC) 0.161 ± 0.006d   0(VC) 0.261 ± 0.009e  
0(CC) 0.502 ± 0.003a   0(CC) 0.492 ± 0.008a  
  1. a-eData in same column without same superscript (a–e) differ significantly(p < 0.05)
  2. GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control